MK 912
Alternative Names: L 657743; MK-912Latest Information Update: 18 Feb 2008
At a glance
- Originator Merck & Co
- Class Antidepressants
- Mechanism of Action Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 14 Dec 1999 Phase-II clinical trials for Depression in USA (PO)
- 23 Jun 1997 No-Development-Reported for Depression in USA (PO)